Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 2/20 | 0.47 |
| ▸ | NOS2 | P35228 | 2/20 | 0.47 |
| ▸ | NOS1 | P29475 | 1/20 | 0.47 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.35 |
| ▸ | CCR1 | P32246 | 1/20 | 0.31 |
| ▸ | CCR5 | P51681 | 1/20 | 0.31 |
| ▸ | CCR8 | P51685 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19904154 | 0.81 | CCR1 (0.32) | NOS3NOS2NOS1CCR1CCR5 | |
| SCHEMBL20125043 | 0.81 | NOS3 (0.54) | NOS3NOS2NOS1CYP2A6CCR1 | |
| SCHEMBL8296665 | 0.73 | NOS3 (0.54) | NOS3NOS2NOS1CYP2A6CCR1 | |
| SCHEMBL20124974 | 0.73 | NOS3 (0.54) | NOS3NOS2NOS1CYP2A6CCR1 | |
| SCHEMBL20746021 | 0.72 | PLAU (0.44) | NOS3NOS2NOS1 | |
| SCHEMBL20721716 | 0.72 | PLAU (0.44) | NOS3NOS2NOS1 | |
| SCHEMBL24217880 | 0.71 | NOS3 (0.48) | NOS3NOS2NOS1 | |
| SCHEMBL24466707 | 0.70 | NOS3 (0.41) | NOS3NOS2NOS1CCR1CCR5 | |
| SCHEMBL8341853 | 0.70 | NOS3 (0.50) | NOS3NOS2NOS1CYP2A6CCR1 | |
| SCHEMBL16130316 | 0.70 | TDP1 (0.45) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230192709-A1 | FGFR INHIBITORS AND METHODS OF USE THEREOF | RELAY THERAPEUTICS, INC. | 2023-06-22 | — | — | US | disclosed |
| US-20230104574-A1 | FGFR INHIBITORS AND METHODS OF USE THEREOF | D.E. SHAW RESEARCH, LLC | 2023-04-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230192709-A1 | FGFR INHIBITORS AND METHODS OF USE THEREOF | FGFR3, FGFR2, FGFR1 | NOS3 4329/4885NOS2 4664/4885NOS1 4605/4885 |
| US-20230104574-A1 | FGFR INHIBITORS AND METHODS OF USE THEREOF | FGFR3, FGFR2, FGFR1 | NOS3 4329/4885NOS2 4664/4885NOS1 4605/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.